HR of death in patients with AAV across subgroups identified by multivariable Cox regression
| HR | LCL HR | UCL HR | p Value | |
| Female | 1 | (reference) | ||
| Male (0–1.85 years) | 2.04 | 0.99 | 4.20 | 0.053 |
| Male (1.85–8.5 years) | 0.90 | 0.49 | 1.67 | 0.747 |
| Male (>8.5 years) | 0.35 | 0.13 | 0.94 | 0.036 |
| Age (1-year increase) | 1.09 | 1.07 | 1.12 | <0.001 |
| Diagnosis GPA | 1 | (reference) | ||
| Diagnosis EGPA | 0.60 | 0.09 | 4.14 | 0.606 |
| Diagnosis MPA | 1.40 | 0.80 | 2.44 | 0.234 |
| ANCA PR3 | 1 | (reference) | ||
| ANCA MPO | 0.94 | 0.57 | 1.54 | 0.807 |
| ANCA negative | 2.24 | 0.46 | 11.00 | 0.320 |
| CKD 1–2 | 1 | (reference) | ||
| CKD 3 | 1.14 | 0.56 | 2.36 | 0.713 |
| CKD 4 | 1.75 | 0.89 | 3.45 | 0.108 |
| CKD 5 | 2.51 | 1.30 | 4.83 | 0.006 |
AAV, ANCA-associated vasculitides; ANCA, antineutrophil cytoplasmatic antibodies; CKD, chronic kidney disease; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; LCL, lower confidence limit; MPA, microscopic granulomatosis; MPO, myeloperoxidase; PR3, proteinase 3; UCL; upper confidence limit.